KITABIS PAK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KITABIS PAK (KITABIS PAK).
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and incorporation of incorrect amino acids into the peptide chain.
| Metabolism | Primarily eliminated unchanged by glomerular filtration; minimal hepatic metabolism. |
| Excretion | Primarily renal (90% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for <10%. |
| Half-life | 3-4 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for CrCl <30 mL/min. |
| Protein binding | 0-10%; primarily binds to albumin and α1-acid glycoprotein. |
| Volume of Distribution | 0.23-0.35 L/kg; indicates distribution primarily into extracellular fluid. Clinical meaning: Low Vd correlates with poor penetration into cells and CNS. |
| Bioavailability | Oral: <1%; IM: 50-60%; nebulized: lung deposition 10-15% of nominal dose, with negligible systemic bioavailability (<1%). |
| Onset of Action | IM: 30 minutes; IV: immediately; inhalation (nebulized): 15 minutes. |
| Duration of Action | IM/IV: 6-8 hours; inhalation: 6-12 hours. Clinical note: Sustained lung concentrations with nebulized therapy, but systemic levels minimal. |
| Molecular Weight | 467.52 |
Inhaled tobramycin: 300 mg twice daily, 28 days on, 28 days off. Administered via nebulizer.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for GFR >= 50 mL/min. For GFR < 50 mL/min: use with caution; consider monitoring serum tobramycin concentrations. For GFR < 30 mL/min: not recommended. |
| Liver impairment | No specific dose adjustment required; tobramycin is primarily renally eliminated. Caution in severe hepatic impairment due to potential concurrent renal dysfunction. |
| Pediatric use | Children aged 6 years and older: 300 mg twice daily via nebulizer. For children <6 years: safety and efficacy not established. |
| Geriatric use | No specific dose adjustment based on age alone. Monitor renal function and adjust dose according to GFR. Increased risk of ototoxicity and nephrotoxicity. |
| 1st trimester | Avoid. Tobramycin has known teratogenic potential; ototoxicity risks exist. Use only if benefit outweighs risk. |
| 2nd trimester | Use with caution. Consider alternative if possible. Monitor renal function and hearing in mother. |
| 3rd trimester | Use with caution. Risk of fetal ototoxicity and nephrotoxicity. Avoid near term if possible. |
Clinical note
Comprehensive clinical and safety monograph for KITABIS PAK (KITABIS PAK).
| Placental transfer | Tobramycin crosses the placenta. Cord blood concentrations are about 20-30% of maternal serum levels. Fetal plasma levels may reach therapeutic levels, posing risk of ototoxicity. |
| Breastfeeding | Tobramycin is poorly absorbed orally, but infant risk is considered low with maternal use. However, observe infant for diarrhea, candidiasis, or blood in stool. The use of inhaled tobramycin results in minimal systemic absorption, likely compatible with breastfeeding. |
■ FDA Black Box Warning
May cause nephrotoxicity, ototoxicity, and neuromuscular blockade. Monitor renal function and hearing. Avoid concurrent use with other nephrotoxic or ototoxic drugs.
| Serious Effects |
Hypersensitivity to tobramycin or any aminoglycosideMyasthenia gravisPreexisting severe renal impairment (unless life-threatening infection and no alternative)
| Precautions | Monitor renal function, eighth cranial nerve function, and serum drug levels. Use caution in patients with renal impairment, myasthenia gravis, or hypocalcemia. Increased risk of nephrotoxicity with prolonged use or high doses. |
| Food/Dietary | No specific food interactions reported. Avoid concurrent use with nephrotoxic agents (e.g., NSAIDs, loop diuretics) or ototoxic drugs. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | KITABIS PAK (tobramycin inhalation solution) is an aminoglycoside antibiotic. Animal studies have shown evidence of ototoxicity and nephrotoxicity in fetuses following high-dose systemic administration. However, inhaled tobramycin results in minimal systemic absorption. FDA Pregnancy Category D: Positive evidence of human fetal risk but potential benefits may warrant use in pregnant women with cystic fibrosis. First trimester: Theoretical risk of ototoxicity; use only if clearly needed. Second/third trimester: Risk of fetal ototoxicity and nephrotoxicity with systemic accumulation; pulmonary delivery reduces risk. Avoid if alternative antibiotics available. |
| Fetal Monitoring | Baseline and periodic audiometry (especially high-frequency) and renal function tests (serum creatinine, BUN) in mother. Monitor serum tobramycin levels if systemic absorption suspected (e.g., concurrent IV antibiotics). Fetal monitoring: Serial ultrasound for growth and amniotic fluid volume if used long-term. Assess for fetal ototoxicity (hearing assessment after birth if significant exposure). |
| Fertility Effects | No specific human studies on fertility; animal studies with systemic aminoglycosides have shown no impairment of fertility. Inhaled tobramycin has limited systemic absorption, making direct reproductive toxicity unlikely. However, underlying cystic fibrosis may affect fertility independent of drug. |
| Clinical Pearls | Kitabis Pak (tobramycin inhalation powder) is used for cystic fibrosis patients with Pseudomonas aeruginosa. Administer via the T-326 inhaler; do not swallow capsules. Monitor renal function and audiometry due to potential nephrotoxicity and ototoxicity. Avoid use in patients with known hypersensitivity to aminoglycosides. Spirometry before and during therapy is recommended. |
| Patient Advice | Use the T-326 inhaler only; do not use with any other device. · Do not swallow the capsules; they are for inhalation only. · Rinse mouth with water after each use to reduce the risk of oral candidiasis. · Store capsules in the refrigerator; do not freeze or expose to heat. · Report hearing loss, tinnitus, dizziness, or changes in urine output immediately. · Complete the full course as prescribed even if feeling better. |